Hepatotoxicity is a well-recognized adverse effect of VPA. 1, 2 VPA hepatotoxicity is believed to be mediated by its effect on hepatocytes mitochondria. 11 VPA-induced inhibition of mitochondrial β-oxidation of fatty acids, impairment of gluconeogenesis, interference with urea synthesis, and inhibition of oxidative phosphorylation have been reported in liver preparations. [11] [12] [13] The involvement of mitochondria in the pathophysiology of VPA-induced FS has not been evaluated so far. On the hand, supplementation with carnitine offers beneficial effects in patients with VPA-induced liver injury. 14 Hence, we investigated whether carnitine could improve VPA-induced FS in this study.
Understanding the mechanism(s) of VPA-induced FS can be useful for developing new preventive/therapeutic strategies against this complication. The current study was designed to evaluate the effect of VPA on rat kidney. Different serum and tissue biomarkers, along with the effect of VPA on kidney mitochondria have been evaluated here. Moreover, the potential protective effect of carnitine on the VPA-induced renal injury was investigated in this study. Kits for evaluating serum biomarkers of renal injury were obtained from Pars Azmun (Tehran, Iran). Ethylenediaminetetraacetic acid (EDTA), 5, 5-bis-dithio-nitro benzoic acid (DTNB), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), meta-Phosphoric acid, n-Butanol, and 2-Amino-2-hydroxymethyl-propane-1, 3-diol-hydrochloride (Tris-HCl), were obtained from Merck (Darmstadt, Germany). All salts used for making buffer solutions were of analytical grade and obtained from Merck (Darmstadt, Germany).
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (n = 32) weighing 200-250 g were obtained from the Laboratory Animal Breeding Center, Shiraz University of Medical Sciences, Shiraz, Iran. Animals were housed in an environmental temperature of 23 ± 1°C with a 40% of relative humidity. Rats had free access to tap water and a standard pellet chow during experiments. All procedures involving animal use were in accordance with the guidance for care and use of experimental animals and were approved by a local ethic committee in Shiraz University of Medical Sciences, Shiraz, Iran (94-01-36-10650).
Experimental setup
Animals were randomly allotted into four groups (n = 8 in each group). Rats were treated as follows: (i) Control (Vehicletreated group), (ii) VPA (250 mg/kg per day, i.p); (iii) VPA (500 mg/kg per day, i.p); (iv) VPA (500 mg/kg per day, i. p) + Carnitine (100 mg/kg per day, i.p). Normal saline was used as valproic acid and carnitine vehicle (2.5 mL/kg). Carnitine was administered 2 h after VPA. In the current investigation, carnitine (100 mg/kg, i.p) cause no kidney injury when it was administered alone. It has been previously reported that a dose of 500 mg/kg per day of valproic acid for 15 consecutive days caused marked renal injury in rats. 15 At the end of experiments (At day 16 th , 24 h after the final dose of VPA), animals were anesthetized (ketamine/xylazine; 100/10 mg/kg, i.p) and their blood and kidney were collected.
Serum biochemistry
Blood was collected from the abdominal aorta, transferred to standard tubes (Improvacuter; gel and clot activator-coated tubes; Guangzhou, China) and centrifuged (3000 g, 10 min, 4°C) to prepare serum. A Mindray BS-200 auto analyzer and standard kits were employed to assess serum gamma-glutamyl transpeptidase (γ-GT), alkaline phosphatase (ALP), Creatinine (Cr), glucose, phosphate, calcium, uric acid and blood urea nitrogen (BUN). 16 Serum sodium and potassium level were assessed by a flame photometer (Clinical Flame Photometer, Sherwood Scientific, UK).
Kidney histopathology
For histopathological assessments, samples of kidney tissue were fixed in a buffered formalin solution (0.4% sodium phosphate monobasic, NaH 2 PO 4 , 0.64% sodium phosphate dibasic, Na 2 HPO 4 , and 10% formaldehyde in distilled water; pH = 7.4). Finally, paraffin-embedded sections (5 μm) of tissue were stained with haematoxylin and eosin (H&E) and Masson trichrome (for renal interstitial fibrosis). 17 Renal histopathological changes were scored as previously described based on a model of toxic nephropathy. 18 Samples were analyzed by a pathologist in a blind fashion.
Kidney tissue reactive oxygen species (ROS) formation
Kidney samples (200 mg) were homogenized in ice-cooled Tris-HCl buffer (40 mM, pH = 7.4) (1:10 w/v). Then, 100 μL of tissue homogenate was mixed with 1 mL of Tris-HCl buffer (40 mM, pH = 7.4) and 5 μL of 2 0 , 7 0 -dichlorofluorescein diacetate (Final concentration 10 μM). The mixture was incubated in dark for 30 min at 37°C (Gyromax incubator shaker). Finally, the fluorescence intensity of the samples was assessed using an FLUOstar Omega multifunctional microplate reader (λ excitation = 485 nm and λ emission = 525 nm). 16, 19 Tissue lipid peroxidation
Thiobarbituric acid reactive substances (TBARs) were assessed in kidney tissue as an index of lipid peroxidation. Briefly, 1 mL of kidney tissue homogenate (10% w/v in KCl, 1.15%) was added to a reaction mixture consisted of thiobarbituric acid (0.375%, w/v), trichloroacetic acid (15%; w/v), and hydrochloric acid (0.2 N) (pH = 2). Samples were mixed well and heated in boiling water (100°C, 45 min). 20 Finally, 2 mL of n-butanol was added and vigorously mixed. Samples were centrifuged (3000 g for 5 min) and the absorbance of developed color in n-butanol phase was measured at 532 nm using an Ultrospec 2000®UV spectrophotometer (Uppsala, Sweden).
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Kidney glutathione content
Tissue samples (200 mg) were homogenized in 8 mL of icecooled EDTA solution (20 mM). Then, 5 mL of the prepared homogenate was mixed with 4 mL of distilled water (4°C) and 1 mL of trichloroacetic acid (50% w/v). The mixture was centrifuged (10000 g, 4°C, 15 min). Then, 2 mL of the supernatant was mixed with 4 mL of Tris buffer (0.4 M, pH = 8.9), and 100 μL of Ellman's reagent (DTNB, 0.01 M in methanol). Finally, the absorbance of developed color was measured at 412 nm using an Ultrospec 2000 UV spectrophotometer (Uppsala, Sweden). form by the action of electron-donating antioxidants. 22 In the current study, the working FRAP reagent was freshly prepared by mixing 10 volumes of acetate buffer (300 mmol/L, pH 3.6), with 1 volume of TPTZ (10 mmol/L in 40 mmol/L hydrochloric acid) and 1 volume of ferric chloride (20 mmol/L). Kidney tissue was homogenized in an ice-cooled Tris buffer (250 mM Tris-HCl, 200 mM sucrose and 5 mM DTT, pH = 7.4). Then, 50 μL of tissue homogenate and 150 μL of deionized water was added to 1.5 mL of the FRAP reagent. The reaction mixture was incubated at 37°C for 5 min. Finally, the absorbance of developed color was measured at 595 nm by an Ultrospec 2000 UV spectrophotometer (Uppsala, Sweden). 23 
Kidney mitochondria isolation
Rat kidneys were washed and minced in an ice-cold buffer medium (70 mM mannitol, 220 mM sucrose, 2 mM HEPES, 0.5 mM EGTA and 0.1% BSA, pH = 7.4). Minced tissue was transported into a fresh buffer (5 mL buffer/1 g of the kidney) and homogenized. Mitochondria were isolated by differential centrifugation of the kidney homogenate. 24 First, unbroken cells and nuclei were pelleted at 1000 g for 10 min at 4°C; second, the supernatant was centrifuged at 10000 g for 10 min at 4°C to pellet the mitochondria. This step was repeated three times using fresh buffer medium. Final mitochondrial pellets were suspended in a buffer containing 70 mM mannitol, 220 mM sucrose, 2 mM HEPES, and 0.5 mM EGTA, pH = 7.4, except for the mitochondria used to assess ROS production, mitochondrial depolarization and mitochondrial swelling, which were suspended in respiration buffer (320 mM Sucrose,10 mM Tris, 20 mM MOPS, 50 μM EGTA, 500 μM MgCl 2 , 0. Mitochondrial succinate dehydrogenase activity (MTT assay)
The 3-(4, 5-dimethylthiazol-2-yl)-2, the 5-diphenyltetrazolium bromide (MTT) assay was applied as a colorimetric method for determination of mitochondrial succinate dehydrogenase activity (SDA) as previously described. 26, 27 Briefly, a mitochondrial suspension (0.5 mg protein/mL) was incubated with 0.4% of MTT at 37°C for 30 min. The product of purple formazan crystals was dissolved in 1 mL dimethyl sulfoxide (DMSO) and the optical density (OD) at 570 nm was measured with an EPOCH plate reader (Bio-Tek Instruments, Highland Park, USA).
Mitochondrial depolarization
Mitochondrial uptake of the cationic fluorescent dye, rhodamine 123, has been used for the estimation of mitochondrial depolarization. 24, 28, 29 Rhodamine 123, accumulates in intact mitochondria by facilitated diffusion. When the mitochondrion is damaged and depolarized, there is no facilitated diffusion and the amount of rhodamine 123 in the supernatant is increased. In the current investigation, the mitochondrial fractions (0.5 mg protein/mL) were incubated with 10 μM of rhodamine 123 in the MMP assay buffer for 30 min. Afterward, samples were centrifuged (15 000 g, 1 min, 4°C) and the fluorescence intensity of the supernatant was monitored using a FLUOstar Omega multifunctional microplate reader (λ excitation = 485 nm and λ emission = 525 nm).
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Reactive oxygen species (ROS) in isolated kidney mitochondria 2 0 , 7 0 -dichlorofluorescein diacetate (DCFH-DA) was used as a fluorescent probe to assess mitochondrial ROS formation.
Valproic acid-induced Fanconi syndrome
Briefly, isolated kidney mitochondria were placed in the respiration buffer. Then, 5 μL of DCFH-DA was added (Final concentration, 10 μM) and the mixture was incubated for 30 min in the dark. The fluorescence intensity of samples was measured using a FLUOstar Omega multifunctional microplate reader (λ excitation = 485 nm and λ emission = 525 nm). 24, 30 Mitochondrial swelling Analysis of mitochondrial swelling was estimated through changes in light scattering as monitored spectrophotometrically at 540 nm (25°C). 24, 30 Briefly, isolated mitochondria were suspended in swelling buffer and the absorbance was measured at 540 nm during 70 min of incubation using an EPOCH plate reader (Bio-Tek Instruments, Highland Park, USA). A decrease in absorbance indicates an increase in mitochondrial swelling.
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Mitochondrial glutathione (GSH) content
Mitochondrial GSH level was determined with a method using Ellman reagent (5,5-dithiobis-2-nitrobenzoic acid, DTNB). 31 The mitochondrial suspensions (0.5 mg/mL, in phosphate buffer, pH = 7.4) were treated with 250 μL of trichloroacetic acid (10% w/v) to extract mitochondrial glutathione. The mixture was centrifuged (15000 g, 10 min, 4°C) to remove denatured proteins. Afterward, 100 μL of DTNB (0.04% in phosphate buffer) was added and the absorbance of samples was recorded at 412 nm with an EPOCH plate reader (BioTek Instruments, Highland Park, USA).
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Lipid peroxidation in isolated kidney mitochondria
Thiobarbituric acid-reactive substances (TBARS) test was used for lipid peroxidation assay in isolated kidney mitochondria. 24 As previously mentioned, sucrose interferes with the TBARS assay. 24 Hence, isolated mitochondria were washed once (to remove sucrose) in ice-cooled MOPS-KCl buffer (50 mM MOPS, 100 mM KCl, pH = 7.4), and re-suspended in MOPSKCl buffer. 24 Afterward, the mitochondrial suspension was added with twice its volume of a mixture containing trichloroacetic acid (15% w/v), thiobarbituric acid (0.375%), HCl (0.24 N) and Trolox (0.5 mM). Samples were heated for 15 min at 100°C. 24 After centrifugation (15 000 g, 10 min), the absorbance of the supernatant was measured at 532 nm using an EPOCH plate reader (BioTek Instruments, Highland Park, USA).
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Mitochondrial ATP level
Based on a previously reported procedure, mitochondrial ATP level was assessed by HPLC. 32 Briefly, isolated mitochondria (0.5 mg protein/mL) were treated with ice-cooled 0.2 M perchloric acid and centrifuged (10 min, 13000, rpm, 4°C). Afterward, the supernatant (100 μL) was treated with its equivalent volume of ice-cooled 1 M KOH solution. Samples (60 μL) were injected into an HPLC system consisted of an LC-18 column (μ-Bondapak, 15 cm). The mobile phase was composed of KH 2 PO 4 (215 mM), tertiary butyl ammonium sulfate (2.3 mM), KOH (1 M, 0.4%) and acetonitrile (4%). The flow rate was 1 mL/min and the UV detector in this system was set at 254 nm. 32 There was a good linear relationship among standard ATP concentrations at a range of 0.0-0.6 μM against its peak area with correlation coefficient being 0.9944.
Statistical analysis
Data are given as the Mean ± SEM. Data comparison was performed by the one-way analysis of variance (ANOVA) with Tukey's multiple comparison test as a post hoc. P < 0.05 was considered significant.
RESULTS
Valproic acid-treated animals developed biochemical evidence of renal injury and FS (Table 1) . Elevated serum GGT, ALP, Cr, and BUN along with hypokalaemia, hypophosphataemia, and a decrease in serum uric acid, were detected in VPA-treated animals ( Table 1) . Administration of carnitine significantly decreased serum biomarkers of renal injury in VPA group (Table 1) . There was no significant difference in almost all the parameters assessed when two doses of VPA (250 and 500 mg/kg, i.p) were compared. Although the effect of VPA on the biochemical markers of kidney injury doesn't seem to be dose-dependent, several biochemical parameters were significantly higher in VPA 500 mg/kg treated group in comparison with VPA 250 mg/kg (Table 1) . Previous investigations also mentioned 500 mg/kg of VPA as the nephrotoxic dose of this drug. 6, 15, 33 The level of oxidative stress markers in kidney was significantly changed in VPA-treated animals (Fig. 1) . It was found that VPA caused an increase in kidney ROS formation and lipid peroxidation (Fig. 1) . Moreover, renal glutathione reservoirs were depleted and tissue antioxidant capacity was defected in VPA-treated rats (Fig. 1) . Carnitine (100 mg/kg) significantly increased GSH levels and the antioxidant capacity of kidney tissue in VPA-treated animals (Fig. 1) . Moreover, kidney ROS and LPO levels were significantly decreased when VPA-treated rats received carnitine (100 mg/kg, i.p.) (Fig. 1) .
Histopathological presentation of VPA-induced renal injury included interstitial nephritis, tissue necrosis, and atrophy (Fig. 2B, C and Table 2 ). The histopathological changes in VPA-treated animals at a dose of 250 mg/kg, were evident as mild interstitial nephritis (Fig. 2, D) . It was found that carnitine (100 mg/kg) hampered renal tissue injury induced by VPA (500 mg/kg, i.p.) (Fig. 2, E) . We found no sign of kidney tissue fibrosis in VPA-treated animals (Masson trichrome staining) when it was compared with control (vehicle-treated) group (Fig. 3) . Liver histopathological changes including steatosis, Fig. 1 Kidney tissue reactive oxygen species (ROS) formation, lipid peroxidation, glutathione content, and total antioxidant capacity. Data are shown as Mean ± SD (n = 8). In carnitine-treated group, animals received valproic acid (VPA) (500 mg/kg per day) plus carnitine (100 mg/kg per day) for 15 consecutive days. *Indicates significantly different as compared with control group (P < 0.001).
a Indicates significantly different as compared with VPA-treated animals (P < 0.001).
ns
: not significant as compared with control group. Carn, carnitine. Data are given as Mean ± SD (n = 8). VPA, Valproic acid. *Indicates significantly different as compared with control animals (P < 0.01). aIndicates significantly different as compared with VPA (250 mg/kg)-treated group (P < 0.01). bIndicates significantly different as compared with VPA (500 mg/kg)-treated group (P < 0.01).
Valproic acid-induced Fanconi syndrome necrosis, and inflammation were also detected in VPA-treated groups (Data not shown). The effect of VPA was not dose-dependent at the mitochondrial level. It was found that mitochondria isolated from VPAtreated animals showed marked decrease in succinate dehydrogenase (SDA) activity (MTT assay) (Fig. 4) . Further assessment of kidney mitochondria, derived from VPA-treated groups, revealed a marked increase in mitochondrial swelling, mitochondrial depolarization, and an increase in mitochondrial ROS level (Fig. 4) . It was also detected that mitochondrial glutathione stores and ATP level were decreased in VPA-treated animals (Fig. 5) . VPA administration (500 mg/kg) also increased mitochondrial lipid peroxidation (Fig. 5) . We found that carnitine (100 mg/kg) co-administration to VPA-treated rats, abrogated VPA-induced mitochondrial dysfunction in the kidney (Figs 4 and 5) .
DISCUSSION
There is evidence of kidney injury in patients treated with VPA. 3, 5, 8, [34] [35] [36] However, the mechanism of VPA-induced renal dysfunction remains obscure. In the current investigation we have demonstrated mitochondrial dysfunction and increased oxidative stress in the kidney. Oxidative stress constitutes an important risk factor for tissue damage and organ dysfunction. Oxidative stress is involved in the activation of several signalling pathways, leading to the activation of transcription factors, gene expression, and induction of apoptosis. 37 Toxicity of VPA on renal tubular cells has been demonstrated both in vitro and in vivo. [38] [39] [40] Renal tubular disorder and increased levels of BUN, Cr, and kidney tissue histopathological changes are detected in VPA-treated animals. 6, 9 VPA inactivates antioxidant enzymes. 41, 42 Our results are in consensus with the other investigations, which quoted that oxidative stress developed in renal tissue after VPA . No significant histopathological changes were detected in carnitine-treated animals (E; VAP 500 mg/kg + Carnitine 100 mg/kg). Scale bar, 1000 μm. administration. 6, 12, 15, 33 We found that VPA elevated kidney ROS levels, reduced tissue antioxidant activity, increased lipid peroxidation and depleted renal glutathione stores. Moreover, we found that renal mitochondrial function was hampered in VPA-treated animals. All these data indicate the contribution of oxidative stress, mitochondrial dysfunction, and its consequent events in VPA-induced renal injury and FS. Oxidative stress might be a cause or a consequence of mitochondrial dysfunction. Hence, VPA-induced ROS formation might deteriorate mitochondrial injury and vice versa.
In the current investigation, we found no sign of tissue fibrosis in the kidney of VPA-treated animals as assessed by Masson trichrome staining (Fig. 3) . VPA may cause kidney fibrosis at other doses or after longer administration.
The molecular mechanisms controlling proximal tubule reabsorption of proteins, ions, and other solutes have well been elucidated. On the other hand, FS is characterized by multiple transport defects in the kidney. 10 Impaired basolateral sodium and potassium adenosine triphosphate (Na + , K + -ATPase) activity is the physiological characteristic of the FS. 8, 10 Renal proximal tubules have a high metabolic rate and generate more than 95% of their ATP by means of oxidative phosphorylation. 43 Proximal tubular cells are highly sensitive to low ATP and energy crisis. 43, 44 Energy metabolism disorders can affect almost any organ. In the kidney, ions and electrolytes reabsorption is an energy-dependent process. Na + /K + ATPase pump consumes ATP molecules to reabsorb ions and electrolytes into the blood. 45 High and constant dependence of proximal tubular cells on energy highlights the importance of mitochondria. The effect of VPA on kidney mitochondria has not been investigated so far. In the current study, we found that kidney mitochondrial ATP level significantly dropped in VPA-treated animals. Hence, VPA-induced mitochondrial dysfunction might lead to the energy crisis in renal proximal tubule cells. Valproic acid-induced mitochondrial toxicity has been shown in the liver. 11 Adverse mitochondrial events associated with VPA in the liver include inhibition and decreased the activity of mitochondrial complexes Ι and V, inhibition of oxygen consumption and ATP synthesis, impaired inner mitochondrial membrane matrix organization, inhibition of mitochondrial β-oxidation, impaired mitochondrial oxidative phosphorylation, and vacuolar fragmentation. [11] [12] [13] In the current investigation, we found that kidney mitochondria might also be a potential target for VPA to induce kidney injury and FS. Discontinuation of VPA may cause remission of symptoms within weeks but can take up to months and even years. 4, 36 Hence, antioxidants and mitochondrial protective agents might prevent injury or enhance the remission of patients with VPAinduced FS.
Carnitine has been recognized to possess a variety of biological and pharmacological activities, including a cofactor for the transportation of free fatty acid from cytosol to the mitochondria. 46 Carnitine also acts as an antioxidant and radical scavenger. 47 Recent research has shown that some pathological conditions benefit from exogenous carnitine supplementation. [48] [49] [50] [51] The protective effect of carnitine in different models of renal injury has also been reported. [52] [53] [54] Supplementation with carnitine offers beneficial effects in patients with VPA-induced liver injury. 14 It has been shown that carnitine showed a good safety profile in patients with acute VPA overdose. 55, 56 In the current study, we found that carnitine effectively mitigated VPA-induced renal injury and mitochondrial dysfunction. Carnitine (100 mg/kg, i.p.) along with VPA, significantly restored tissue antioxidant capacity and effectively encountered VPA-induced oxidative stress in the kidney (Fig. 1) . Furthermore, mitochondria isolated from the kidney of the carnitine-treated group had better function (Figs 4 and 5) . The antioxidant and radical scavenging properties of carnitine might be involved in this process. As risk assessment investigations revealed a safe profile for carnitine in humans, 57 carnitine might have therapeutic potential against VPA-induced FS. The insignificant changes in serum Cr and fibrosis in the current study might reflect the mild kidney injury in VPA-treated rats (Table 1 ). This might also be due to the duration of exposure to VPA. On the other hand, the occurrence of oxidative stress and mitochondrial dysfunction in VPA-treated animals might reflect the early signs of VPA-induced nephrotoxicity.
Other factors such as dehydration, high protein diet and also VPA-induced hepatic injury (which is concurrently occurs in VPA-treated animals) could also affect serum biomarkers of VPA-induced renal damage (e.g. BUN). Hence, monitoring the urine analytical parameters and glomerular/tubular function, as well as more precise biomarkers of renal injury could help monitoring VPA-induced nephrotoxicity in animal models and/or patients.
Previous studies mentioned the dose of 500 mg/kg, i.p for 14 consecutive days as the nephrotoxic dose of VPA. 6, 16, 34 Our investigation also revealed the renal injury, oxidative stress, and mitochondrial dysfunction when animals received VPA 500 mg/kg. Hence, VPA could be applicable as an animal model of FS. However, based on the insignificant change in some biomarkers of renal injury (e.g. Cr), we suggest a longer time of drug administration for a more reliable animal model of VPAinduced FS. Several investigations indicate the role of reactive metabolites in VPA-induced cytotoxicity, organelle dysfunction, and oxidative stress. 61, 62 There is no study on VPA biotransformation and potential toxic intermediates formation in the kidney. Hence, future investigations might shed light on the role of drug biotransformation in the mechanism of VPA-induced mitochondrial dysfunction, renal injury, and FS. Current data might provide insights to determine the mechanisms responsible for the VPA-induced renal injury. Based on this investigation, we propose that prexisting mitochondrial defects might exacerbate VPA-induced FS. Moreover, these data suggest carnitine as a potential nephroprotective agent against VPA-induced renal injury. On the other hand, measuring VPA level in the kidney tissue, as well as in the mitochondrial preparations might help to further characterization of VPA-induced FS and mitochondrial dysfunction. Moreover, determination of urine analytical parameters and glomerular/tubular function could greatly enhance our understanding of the magnitude of injury induced by FSinducing xenobiotics.
